Erectile Dysfunction Drugs Market Scenario
Global erectile dysfunction drugs market is expected to register a CAGR of 3.5% during the forecast period of 2019 to 2025 with a market value of USD 2930 million in 2025.
Erectile dysfunction (ED) is defined as persistent difficulty achieving and maintaining an erection sufficient to have sex.
The global erectile dysfunction drugs market is driven by factors such as increasing number of men suffering from this disorder, rising geriatric population and patent expiry of number of blockbuster drugs.
Additionally, increasing manufactures of generic drugs coupled with rising adoption of a sedentary lifestyle along with the associated stress is anticipated to fuel the market growth.
For instance, according to The Massachusetts Male Aging Study (MMAS), worldwide incidence of erectile dysfunction will increase from 152 million men in 1995 to 322 million men by the year 2025.
On the other hand, poor patient adherence to erectile dysfunction drugs is projected to hamper the growth of the market during the assessment period.
Moreover, major companies in the market are involved in strategic acquisitions, collaborations, mergers, and new product launch to sustain their position in the market.
For instance, in December 2017, Teva Pharmaceutical Industries Ltd. announces exclusive launch of a generic version viagra tablets in the US.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1313
Erectile Dysfunction Drugs Market Segmentation
The global erectile dysfunction drugs market has been segmented based on and region.
The market, based on drug, has been bifurcated into viagra (sildenafil citrate), cialis (tadalafil), staxyn/levitra (vardenafil), stendra/spedra (avanafil), zydena (udenafil), vitaros (alprostadil cream), and others. The market, on the basis of end user, has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on drug, viagra segment is expected to hold a major share in the market as it is the first Food and Drug Administration (FDA) approved oral treatment for erectile dysfunction. In 1998, Pfizer introduced viagra which is dominating the erectile dysfunction market. Cialis segment is expected to be the fastest growing segment as cialis provides an erection over a longer period than viagra, cialis lasts up to 18 hours, while viagra only lasts for about 4 to 6 hours.
On the basis of end user retail pharmacy segment is expected to be the largest segment as it is available easily in the retail stores. The hospital pharmacy segment is expected to be the fastest growing segment as increasing pool of patient due to increasing awareness and patient education.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The erectile dysfunction drugs market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European erectile dysfunction drugs market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, UK, Italy, Spain, and the rest of Western Europe. The erectile dysfunction drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The erectile dysfunction drugs market in the Middle East & Africa has been divided into the Middle East and Africa.
Key Players
The key players in the global erectile dysfunction drugs market are Pfizer, Inc., Apricus Biosciences Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltd., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd.
Regional Market Summary
The market in the Americas is expected to dominate the global erectile dysfunction drugs market due to the rising prevalence of erectile dysfunction and increasing awareness & patient education in the region. High cases of erectile dysfunction in the US and Canada is expected to drive the market growth. For example, as per the survey, overall prevalence of erectile dysfunction in men aged more than 20 years was 18.4% suggesting that erectile dysfunction affects 18 million men in the US. Furthermore, increasing expenses in research by healthcare bodies engaged in research of novel drugs is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the increasing adoption of a sedentary lifestyle along with the associated stress in the European region. The market in Asia-Pacific is projected to have a fastest growth rate during the forecast period owing to the increasing geriatric population and rising availability of generic drugs. For example, according to The United Nations Population Fund, by 2050, 1 in 4 people in Asia and the Pacific will be over 60 years old. The population of older people (aged over 60) in the region will triple between 2010 and 2050 and will reach close to 1.3 billion people. The incidences of erectile dysfunction increase with the growing age hence Asia-Pacific market will grow fast in the forecasted period. The market in the Middle East & Africa is projected to account for the least share of the global market due to low awareness and patient education in the region.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313
No comments:
Post a Comment